The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.aw

Transient pulmonary opacities/infiltrates (TAPO) (see also under IIj)

Publications

Possick JD

Welcome to the Real World: Understanding the Many Faces of Osimertinib-Related Pneumonitis.

Chest 2022 Nov;162;965-967 — 2022 Nov — 965-967

Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D

Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.

Chest 2022 Nov;162;1188-1198 — 2022 Nov — 1188-1198

Lu H, Dowell J

Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.

In vivo (Athens, Greece) 2020 Jan-Feb;34;315-319 — 2020 Jan-Feb — 315-319